BNTX
BioNTech SE
BNTX has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over BNTX overall, supported by stronger fundamentals and stronger modeled upside.
BNTX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Strong | |
| Strong |
BNTX's cash flow and balance sheet are currently strong, but its revenue and profitability are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BNTX PE Valuation
BNTX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BNTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect BNTX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
BNTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$7.48 | -$5.88 |
| Q1 2026 | -$5.65 | -$2.03 |
| Q4 2025 | -$5.20 | -$2.05 |
| Q3 2025 | -$2.63 | -$0.32 |
| Q2 2025 | -$1.60 | +$0.84 |
| Q1 2025 | -$3.62 | -854% |
| Q4 2024 | -$3.15 | -175% |
| Q3 2024 | -$2.31 | -119% |
BNTX lost $7.48 per share over the past year, and its loss has widened in each of the last four quarters.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BNTX on earnings quality, reporting a profit while its opponent remains loss making.
BNTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $117.3M | -60% |
| Q1 2026 | $133.4M | -34% |
| Q4 2025 | $998.6M | -24% |
| Q3 2025 | $1.7B | +22% |
| Q2 2025 | $289.7M | +103% |
| Q1 2025 | $203.1M | -2.6% |
| Q4 2024 | $1.3B | -20% |
| Q3 2024 | $1.4B | +39% |
BNTX's revenue has slid since its 2022 peak: $117M last quarter, down 60% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -898% | -706 points |
| Q1 2026 | -560% | -268 points |
| Q4 2025 | -26% | -38 points |
| Q3 2025 | -3.1% | -3.9 points |
| Q2 2025 | -192% | +559 points |
| Q1 2025 | -292% | -22 points |
| Q4 2024 | 12% | -23 points |
| Q3 2024 | 0.8% | -7.3 points |
BNTX's operating margin was −898% last quarter, down 706 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BNTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over BNTX on profitability, with a higher operating margin.
BNTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$49.8M | -106% |
| Q1 2026 | -$539.5M | +$1.1B |
| Q4 2025 | $264M | +$932.4M |
| Q3 2025 | $901.1M | +$1.8B |
| Q2 2025 | $777.7M | -56% |
| Q1 2025 | -$1.6B | -$1.1B |
| Q4 2024 | -$668.4M | -153% |
| Q3 2024 | -$865.1M | -218% |
BNTX's free cash flow has turned positive again: $576M over the past year, against −$2.4B the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BNTX on cash flow, with more consistent year-over-year improvement.
BNTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +449K shares |
| 1 year | +4.8% | +11.7M shares |
| 3 years | +5.7% | +13.6M shares |
| 5 years | -2.1% | -5.5M shares |
| Available history | +10% | +23.9M shares |
BNTX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $146.7M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BNTX spent $147M buying back its own shares over the past year, after none the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BNTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -149.4x | Net Cash |
| Q4 2023 | -10.3x | Net Cash |
| Q3 2023 | -3.4x | Net Cash |
| Q2 2023 | -2.3x | Net Cash |
| Q1 2023 | -1.5x | Net Cash |
| Q4 2022 | -1.0x | Net Cash |
| Q3 2022 | -0.9x | Net Cash |
| Q2 2022 | -0.5x | Net Cash |
BNTX has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
BNTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.6 | Neutral |
| Stochastic | 5.7 | Oversold |
BNTX's weekly RSI is 41 (neutral) and its Stochastic is 6 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BNTX PE vs Healthcare Sector
| Metric | BNTX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BNTX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BNTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $91.1 | 6.7% below |
| 20 week MA | $94.6 | 10% below |
| 50 week MA | $96.6 | 12% below |
| 100 week MA | $101.4 | 16% below |
| 200 week MA | $103.6 | 18% below |
BNTX is in a downtrend: it's below all five of its weekly moving averages, and 18% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BNTX on trend strength, trading above more of its moving averages.
BNTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.6 | $97.0 | +198% |
| 2021 | $97.0 | $255.3 | +163% |
| 2022 | $255.3 | $176.0 | -31% |
| 2023 | $176.0 | $105.5 | -40% |
| 2024 | $105.5 | $114.0 | +8% |
| 2025 | $114.0 | $94.5 | -17% |
| 2026 YTD | $94.5 | $85.0 | -10% |
BNTX's yearly returns have swung widely, from +198% in 2020 to −40% in 2023. It's down 10% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BNTX on returns for 2026, with the stronger performance.